Genprex Reports $4.67 Million Net Loss in Q2 2025, Down 28% Year-Over-Year

Genprex, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $4.67 million, a 28% decrease from the $6.50 million loss recorded in the same period of 2024. For the first half of 2025, the company’s net loss was $8.64 million, down 31% from $12.46 million in the prior year. The reduction in losses is attributed to the closure of the Acclaim-2 clinical trial, which led to decreased clinical and manufacturing expenses, as well as cost-cutting measures that reduced overall headcount from 21 employees in June 2024 to 15 in June 2025.

Total operating expenses for the second quarter of 2025 were $4.68 million, down from $6.52 million in the same quarter of 2024. Research and development expenses increased by 50% to $2.50 million, primarily due to differences in clinical trial enrollment and a one-time refund from a contract manufacturer in the previous year. General and administrative expenses saw a significant decline of 55%, totaling $2.18 million, as the company implemented strategies to reduce travel and professional service costs.

As of June 30, 2025, Genprex had cash and cash equivalents of $1.35 million, a decrease from $1.60 million at the end of 2024. The company has not generated revenue from product sales and has an accumulated deficit of $163.44 million. To fund ongoing operations and clinical trials, Genprex has relied on equity financing, raising approximately $7.77 million from the sale of common stock during the first half of 2025.

Strategically, Genprex has made significant developments in its clinical programs. The company is currently enrolling patients in the Phase 2a expansion of its Acclaim-1 trial, which combines its lead oncology candidate, REQORSA, with AstraZeneca’s Tagrisso for treating late-stage non-small cell lung cancer. The FDA has granted Fast Track Designation for this combination therapy. Additionally, Genprex has formed a wholly-owned subsidiary, Convergen Biotech, to focus on its diabetes gene therapy program, which is in preclinical stages.

Looking ahead, Genprex anticipates needing additional capital to support its clinical trials and operations. The company expects to complete interim enrollment for the Acclaim-1 trial by the first quarter of 2026 and is actively seeking stockholder approval for further equity sales under its equity line of credit agreement with Lincoln Park Capital Fund, which allows for up to $12.5 million in funding. The company’s ability to continue as a going concern remains uncertain, contingent on its success in raising additional funds and advancing its clinical programs.